Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
Boston Scientific

Boston Scientific (NYSE: BSX) insider transactions

In the twelve months to 10 November 2026, executives and directors of Boston Scientific reported 3 open-market sales of 178,214 shares ($16.8m) and 10 open-market purchases of 206,362 shares ($10.0m), by 6 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Boston Scientific shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
4 November 2026Mahoney Michael FChairman, President & CEOGift+149,992—149,992Form 4
4 November 2026Mahoney Michael FChairman, President & CEOGift+102,249—252,241Form 4
1 November 2026O'Sullivan MiriamSVP, Chief HR OfficerOption exercise+3,871—21,437Form 4
1 November 2026O'Sullivan MiriamSVP, Chief HR OfficerShares withheld for tax−1,872$41.9819,565Form 4
2 September 2026O'Connor Padraig AndrewEVP, Global OperationsOption exercise+1,171—8,459Form 4
2 September 2026O'Connor Padraig AndrewEVP, Global OperationsShares withheld for tax−567$48.377,892Form 4
25 August 2026Morano Susan EDirectorOpen-market purchase+2,040$49.2213,784Form 4
11 August 2026Woodworth EmilySVP, Global Controller and CAODiscretionary transaction+2,930$51.192,930Form 4
10 August 2026Monson JonathanEVP and CFODiscretionary transaction+9,908$50.469,908Form 4
5 August 2026Habiger David CDirectorOpen-market purchase+2,100$47.5917,160Form 4
4 August 2026Habiger David CDirectorOpen-market purchase+140$48.5915,060Form 4
3 August 2026Mahoney Michael FChairman, President & CEOOpen-market purchase+186,240$48.331,590,024Form 4
3 August 2026Mahoney Michael FChairman, President & CEODiscretionary transaction+22,119$48.4322,119Form 4
3 August 2026Habiger David CDirectorOpen-market purchase+1,042$48.0714,920Form 4
31 July 2026Fitzgerald Joseph MichaelEVP & Group Pres, CardiologyDiscretionary transaction+64,198$46.7364,198Form 4
31 July 2026Ludwig Edward JDirectorOpen-market purchase+5,000$45.4830,359Form 4
1 July 2026Monson JonathanEVP and CFOOption exercise+2,087—40,073Form 4
1 July 2026Monson JonathanEVP and CFOShares withheld for tax−1,010$43.0639,063Form 4
28 May 2026Mahoney Michael FChairman, President & CEOGift−386,755—0Form 4
20 May 2026Habiger David CDirectorOpen-market purchase+2,250$55.9213,878Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Boston Scientific page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.